Abstract | BACKGROUND: METHODS: We examined the pharmacokinetic parameters of hydrocortisone administered i.v. as a bolus at a dose of 15 mg/m2 in a 17.3 year-old female patient with classic CAH before and four weeks after institution of flutamide treatment by determining serum cortisol concentrations at 10 min intervals for 6 h following the i.v. bolus of hydrocortisone. RESULTS: Treatment with flutamide resulted in a decrease in cortisol clearance from 420 ml/l to 305 ml/l (27% reduction), and a decrease in volume of distribution from 51.61 to 451 (12.9% reduction). The half-life of cortisol increased from 85.3 min to 102.1 min. CONCLUSIONS:
Flutamide treatment decreases cortisol clearance, thereby prolonging its half-life. These findings indicate that a reduction in the daily dose of glucocorticoid replacement may need to be considered when flutamide is added to the treatment regimen of patients receiving hydrocortisone.
|
Authors | E Charmandari, A Johnston, J W Honour, C G D Brook, P C Hindmarsh |
Journal | Journal of pediatric endocrinology & metabolism : JPEM
(J Pediatr Endocrinol Metab)
Vol. 15
Issue 4
Pg. 435-9
(Apr 2002)
ISSN: 0334-018X [Print] Germany |
PMID | 12008691
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Androgen Antagonists
- Anti-Inflammatory Agents
- Steroids
- Flutamide
- Hydrocortisone
|
Topics |
- Adolescent
- Adrenal Hyperplasia, Congenital
(blood, complications, drug therapy)
- Androgen Antagonists
(pharmacokinetics, therapeutic use)
- Anti-Inflammatory Agents
(therapeutic use)
- Area Under Curve
- Female
- Flutamide
(pharmacokinetics, therapeutic use)
- Half-Life
- Humans
- Hydrocortisone
(blood, therapeutic use)
- Hyperandrogenism
(drug therapy, etiology)
- Steroids
(therapeutic use)
|